Posted by Michael Wonder on 31 Oct 2019
Parallel distributed or parallel imported Maviret and Viekirax remain in high cost protection
28 October 2019 - TLV has reconsidered the subsidy for parallel distributed or parallel imported Maviret and Viekirax and decided that they should continue to be included in the high-cost protection but with changed restrictions.
The changed subsidy limit for Maviret means that the drug is no longer subsidized for patients of all fibrosis grades, but only for the most severely ill patients (fibrosis grades 3 and 4) when treatment with the hepatitis c drugs that are subsidized for all patients is not appropriate.
The changed subsidy limit for Viekirax means that it is no longer restricted to use when treatment with Maviret is not appropriate.
